Kairos Pharma (NYSEAMERICAN:KAPA) Releases Earnings Results

Kairos Pharma (NYSEAMERICAN:KAPA) released its quarterly earnings data on Wednesday. The company reported ($0.06) earnings per share for the quarter, FiscalAI reports.

Kairos Pharma Stock Up 0.7%

KAPA stock traded up $0.00 during midday trading on Thursday, reaching $0.36. The company had a trading volume of 60,014 shares, compared to its average volume of 1,118,402. The firm has a market capitalization of $7.64 million, a PE ratio of -1.19 and a beta of 1.56. The stock has a 50 day moving average price of $0.37 and a 200 day moving average price of $0.51. Kairos Pharma has a fifty-two week low of $0.27 and a fifty-two week high of $2.11.

Institutional Trading of Kairos Pharma

A hedge fund recently bought a new position in Kairos Pharma stock. Two Sigma Investments LP acquired a new position in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 45,789 shares of the company’s stock, valued at approximately $54,000. Two Sigma Investments LP owned about 0.22% of Kairos Pharma at the end of the most recent reporting period.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.